Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics.

Fundamental & clinical pharmacology - 1 Jun 2024

Nakatsugawa Emi, Naito Takafumi, Shibata Kaito, Kitajima Ryo, Kawakami Junichi

Abstract excerpt

BACKGROUND/OBJECTIVES: Clinical responses to naldemedine vary between individuals with advanced cancer. This is a prospective, single-center, observational study aimed to evaluate the influence of genetic polymorphisms and cachexia status on plasma naldemedine and clinical responses. METHODS: Forty-eight patients being treated with naldemedine for opioid-induced constipation under treatment of cancer pain were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Analgesics, Opioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Cachexia

Share to Cytochrome P-450 CYP3A

Share to Naltrexone

Share to Neoplasms

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 38192190
DOI: 10.1111/fcp.12976

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics.PMID 38192190Read ↗

Risk Factors for Opioid-induced Constipation in Cancer Patients: a Single-institution, Retrospective AnalysisSemantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.Semantic proximity Read ↗

Predictors for Effectiveness of Naldemedine in Patients with Cancer Pain: A Retrospective, Single-Institution AnalysisSemantic proximity Read ↗

ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein.Semantic proximity Read ↗

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Semantic proximity Read ↗

Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids.Semantic proximity Read ↗

Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer.Semantic proximity Read ↗

Investigating the orexigenic potential of olanzapine in cancer patients (OLANZAPRIZ): A Systematic ReviewSemantic proximity Read ↗

Genome-wide scan identifies candidate loci related to remifentanil requirements during laparoscopic-assisted colectomy.Semantic proximity Read ↗

A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Semantic proximity Read ↗

Cannabis Use Is Associated With Patient and Clinical Factors in a Population-Based Sample of Colorectal Cancer SurvivorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.